Performance of a HER2 testing algorithm specific for p53‐abnormal endometrial cancer

AIMS: Human epidermal growth factor receptor 2 (HER2) amplification in endometrial cancer (EC) is almost completely confined to the p53‐abnormal (p53abn) molecular subtype and independent of histological subtype. HER2 testing should therefore be molecular subtype‐directed. However, the most optimal...

Descripción completa

Detalles Bibliográficos
Autores principales: Vermij, Lisa, Singh, Naveena, Leon‐Castillo, Alicia, Horeweg, Nanda, Oosting, Jan, Carlson, Joseph, Smit, Vincent, Gilks, Blake, Bosse, Tjalling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518500/
https://www.ncbi.nlm.nih.gov/pubmed/33835523
http://dx.doi.org/10.1111/his.14381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518500/
https://www.ncbi.nlm.nih.gov/pubmed/33835523
http://dx.doi.org/10.1111/his.14381

Ejemplares similares